Salidroside, the active constituents of Rhodiola rosea, is nervous after a while the middle cerebral artery occlusion (tMCAO). However, the impact in other experimental models of stroke are poorly understood. Here, we examined the effects of daily intraperitoneal injections salidroside in rats after permanent MCAO (pMCAO). the volume of cerebral infarction in 1 day after pMCAO was significantly reduced by treatment with 100 mg / kg / day salidroside, but not at 25 or 50 mg / kg / day, and benefits from salidroside increased significantly for at least 7 days of treatment, when it also accompanied by neurologic deficit score decreased.
These observations prompted us to investigate the underlying mechanisms of action salidroside. 100 mg / kg for 1 day salidroside increased Neun, Nrf2 and HO-1 downstream mediator, while reducing NF nuclear p50, IL-6, and TNF. Brusatol, Nrf2 inhibitor, blocked the action salidroside on Nrf2, NF p50, IL-6, and TNF.
Salidroside also increase the ratio of p-PKB / PKB at 1 day after pMCAO even before brusatol. LY294002, PI3K inhibitors, to prevent these effects from salidroside, including those in Neun, p-PKB / PKB, Nrf2, HO-1, and pro-inflammatory mediators. Instead, salidroside no significant effect on brain levels of complement C3 after pMCAO, or on C3 activity as measured by the expression of cerebral Egr1.
Therefore, our findings suggest that salidroside reduce neuroinflammation and neuronal damage by regulating the PI3K / PKB / Nrf2 / NF signaling pathways after pMCAO, and that this neuroprotective effect does not involve modulation of complement C3 activity.
Salidroside Reduces Inflammation and Brain Injury After Permanent Middle Cerebral Artery Occlusion in Rats by Regulating PI3K/PKB/Nrf2/NFκB Signaling Rather than Complement C3 Activity.
Identification of the canonical NF (C-NF) pathway in uveal melanoma and its relation to patient outcomes.
Inflammation of the uveal melanoma (UM) associated with a poor prognosis. This is a rare type of cancer, in which the metastasis is usually fatal within a year. Infiltration with inflammatory infiltration rise to the development of the disease but does not seem to inhibit metastasis. The Canonical NF (C-NF) pathway is known to play an important role in tumor inflammation.
Therefore we, studying the canonical NF protein expression and their prognostic relevance in UM. Our study evaluated the expression of the protein C-NF (p65, p50 and c-Rel) using immunohistochemistry on sections of formalin-fixed 75 MW. Activation of NF subunit is determined on fresh tumor specimens by measuring the activity of DNA-binding core using ELISA NF test. Real-time PCR was performed on frozen matter on 58 tumor. The presence of heterodimers original C-NF (p65 / p50 and c-Rel / p50) was confirmed by co-immunoprecipitation followed by Western blotting.
We observed a high nuclear immunoreactivity of p65, p50 and c-Rel protein in 54, 60 and 41% of cases MW, respectively. C-NF protein expression significantly correlated with environmental parameters associated with inflammation of the UM. Nuclear immunoreactivity of p65 and p50 was associated with lower patient survival (p = 0.041; p = 0.048), whereas c-Rel are not. Our findings suggest that protein C-NF expressed more often in UM with inflammation than those without inflammation. Activation of NF canonical pathway more often in high-risk patients with UM.
Description: Boster Bio Anti-NFkB-p100 (Ab-866) NFKB2 Antibody (Catalog # A01228-1). Tested in WB, IHC, IF applications. This antibody reacts with Human, Mouse, Rat.
Description: Boster Bio Anti-NFkB-p105 (Ab-927) NFKB1 Antibody (Catalog # A00283-1). Tested in WB, IF applications. This antibody reacts with Human, Mouse, Rat.
Description: A polyclonal antibody for NFkB p65 from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with Human A synthesized peptide derived from human NF-kappaB p65. The Antibody is tested and validated for WB, IHC, ICC/IF, IP assays with the following recommended dilutions: WB (1:2000), IHC (1:200), ICC/IF (1:200). This NFkB p65 antibody is unconjugated.
Description: A polyclonal antibody for NFkB p65 from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with Human A synthesized peptide derived from human NF-kappaB p65. The Antibody is tested and validated for WB, IHC, ICC/IF, IP assays with the following recommended dilutions: WB (1:2000), IHC (1:200), ICC/IF (1:200). This NFkB p65 antibody is conjugated to ATTO 390.
Description: A polyclonal antibody for NFkB p65 from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with Human A synthesized peptide derived from human NF-kappaB p65. The Antibody is tested and validated for WB, IHC, ICC/IF, IP assays with the following recommended dilutions: WB (1:2000), IHC (1:200), ICC/IF (1:200). This NFkB p65 antibody is conjugated to ATTO 488.
Description: A polyclonal antibody for NFkB p65 from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with Human A synthesized peptide derived from human NF-kappaB p65. The Antibody is tested and validated for WB, IHC, ICC/IF, IP assays with the following recommended dilutions: WB (1:2000), IHC (1:200), ICC/IF (1:200). This NFkB p65 antibody is conjugated to ATTO 594.
Description: A polyclonal antibody for NFkB p65 from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with Human A synthesized peptide derived from human NF-kappaB p65. The Antibody is tested and validated for WB, IHC, ICC/IF, IP assays with the following recommended dilutions: WB (1:2000), IHC (1:200), ICC/IF (1:200). This NFkB p65 antibody is conjugated to Biotin.
Description: A polyclonal antibody for NFkB p65 from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with Human A synthesized peptide derived from human NF-kappaB p65. The Antibody is tested and validated for WB, IHC, ICC/IF, IP assays with the following recommended dilutions: WB (1:2000), IHC (1:200), ICC/IF (1:200). This NFkB p65 antibody is conjugated to FITC.
Description: Western blot, 0.1-0.5μg/ml, Human, Mouse;_x000D_Immunohistochemistry (Paraffin-embedded Section), 0.5-1μg/ml, Human, Mouse, Rat, By Heat
This observation may help to understand the behavior of high-risk tumors, the upregulation of the protein C-NF NF contributes to tumor aggressiveness.The RELA members of family of transcription factors, p50, and cRel form of homo and heterodimers are inhibited by IκBα, IκBβ, and IκBε. NF members of this family have diverse biological functions, and they are different expression profiles, leading to different concentrations in different tissue types.
Nuclear factor of kappa light polypeptide gene enhancer in B-cells (NF) transcription factor plays an important role in the human immune response. family including homodimers and heterodimers five component proteins, which mediate transcription of different responses and binds preferentially to different DNA sequences.
DNA complex crystal structures showed that the dimers of Rel-homology region (RHR) is structurally very similar. DNA sequences of different preferences together with structural similarities indicate that the dimer may differ in their dynamics.
In this study, we present the first near-complete 15 N, 13 Cα / β, and HN backbone resonance assignment of domain dimerization of two dimer (DD) of NFκBp50) protein (residues 241-351): homodimers and heterodimers of two p50 domains of DD DD p50 to p65. As expected, the two dimers behave very similar, the chemical shift difference between them is mostly concentrated at the dimer interface and arising from certain differences in the amino acid sequence of p50 and p65.
Comparative dynamics of picosecond-nanosecond of homo and heterodimers also showed that the p50-like environment, with a slightly reduced the overall correlation to homodimer as compared to the heterodimer, consistent with a molecular weight slightly smaller. These results show that NMR spectroscopy can be used to explore the subtle changes in the structure and dynamics of which have the potential to provide insight into the differences in specificity that can be exploited in the design of new therapeutic agents. This article is protected by copyright. All rights reserved.
Comparison of backbone dynamics of the p50 dimerization domain of NFκB in the homodimeric transcription factor NFκB1 and in its heterodimeric complex with RelA (p65).
Diets high in n6 / n3 ratio decreased ratio of arachidonic acid and eicosapentaenoic regulate NF / p50 expression in short-term low-dose streptozotocin and high-fructose mouse model of diabetes.
We studied the effect of dietary n6 / n3 ratio and docosahexaenoic (DHA) and eicosapentaenoic (EPA) acid supplementation on fatty acid profile, lipid peroxidation and NFκ / p50 expression in type 2 diabetes treatment consisted of three dietary ratio of n6 / n3: 6 (Control ), 50 (high n6) and 1 (DHA and EPA plus).
Half of the rats in each treatment were made diabetic diet by using fructose / model low-streptozotocin. Control and high n6 loss diet EPA / ARA (arachidonic acid) ratio in the plasma and in the liver tissue showed pro-inflammatory fatty acid profile. High n6 diet also increases 4-HNE and NFκ / p50 expression in liver tissue. These changes are a consequence of a decrease in plasma levels of DHA and EPA and the increase in arachidonic acid content in the liver neutral lipids. Supplementation with DHA and EPA attenuated changes in the ratio of EPA / ARA, which implies the importance of n6 / n3 ratio in type 2 diabetes.
Immunoregulatory effects of polysaccharides new cornucopioides Craterellus (CCP) with a triple-helix structure in immunosuppressive BALB / c mouse model was investigated; moreover, the immune response of BALB / c mouse model in prevention and therapeutic treatment group were treated with PKC explored, and the molecular mechanisms that have been described. It was found that BALB / c mouse model in preventive group treated with CCP (120 and 240 mg kg-1 d-1) have a better immunoregulatory activity.
Description: A polyclonal antibody for NFkB p105 / p50 (pSer893) from Human. The antibody is produced in rabbit after immunization with human synthetic phospho-peptide from human NFkB p105 / p50 around the phosphorylation site of serine 893 (pSer893).. The Antibody is tested and validated for WB, IHC assays with the following recommended dilutions: WB (1:250-1:1000); IHC (1:25-1:100). This NFkB p105 / p50 (pSer893) antibody is conjugated to ATTO 565.
Description: A polyclonal antibody for NFkB p105 / p50 (pSer893) from Human. The antibody is produced in rabbit after immunization with human synthetic phospho-peptide from human NFkB p105 / p50 around the phosphorylation site of serine 893 (pSer893).. The Antibody is tested and validated for WB, IHC assays with the following recommended dilutions: WB (1:250-1:1000); IHC (1:25-1:100). This NFkB p105 / p50 (pSer893) antibody is conjugated to ATTO 633.
Description: A polyclonal antibody for NFkB p105 / p50 (pSer893) from Human. The antibody is produced in rabbit after immunization with human synthetic phospho-peptide from human NFkB p105 / p50 around the phosphorylation site of serine 893 (pSer893).. The Antibody is tested and validated for WB, IHC assays with the following recommended dilutions: WB (1:250-1:1000); IHC (1:25-1:100). This NFkB p105 / p50 (pSer893) antibody is conjugated to ATTO 655.
Description: A polyclonal antibody for NFkB p105 / p50 (pSer893) from Human. The antibody is produced in rabbit after immunization with human synthetic phospho-peptide from human NFkB p105 / p50 around the phosphorylation site of serine 893 (pSer893).. The Antibody is tested and validated for WB, IHC assays with the following recommended dilutions: WB (1:250-1:1000); IHC (1:25-1:100). This NFkB p105 / p50 (pSer893) antibody is conjugated to ATTO 680.
Description: A polyclonal antibody for NFkB p105 / p50 (pSer893) from Human. The antibody is produced in rabbit after immunization with human synthetic phospho-peptide from human NFkB p105 / p50 around the phosphorylation site of serine 893 (pSer893).. The Antibody is tested and validated for WB, IHC assays with the following recommended dilutions: WB (1:250-1:1000); IHC (1:25-1:100). This NFkB p105 / p50 (pSer893) antibody is conjugated to ATTO 700.
Description: A polyclonal antibody for NFkB p105 / p50 (pSer893) from Human. The antibody is produced in rabbit after immunization with human synthetic phospho-peptide from human NFkB p105 / p50 around the phosphorylation site of serine 893 (pSer893).. The Antibody is tested and validated for WB, IHC assays with the following recommended dilutions: WB (1:250-1:1000); IHC (1:25-1:100). This NFkB p105 / p50 (pSer893) antibody is conjugated to Alkaline Phosphatase.
Description: A polyclonal antibody for NFkB p105 / p50 (pSer893) from Human. The antibody is produced in rabbit after immunization with human synthetic phospho-peptide from human NFkB p105 / p50 around the phosphorylation site of serine 893 (pSer893).. The Antibody is tested and validated for WB, IHC assays with the following recommended dilutions: WB (1:250-1:1000); IHC (1:25-1:100). This NFkB p105 / p50 (pSer893) antibody is conjugated to APC .
Description: A polyclonal antibody for NFkB p105 / p50 (pSer893) from Human. The antibody is produced in rabbit after immunization with human synthetic phospho-peptide from human NFkB p105 / p50 around the phosphorylation site of serine 893 (pSer893).. The Antibody is tested and validated for WB, IHC assays with the following recommended dilutions: WB (1:250-1:1000); IHC (1:25-1:100). This NFkB p105 / p50 (pSer893) antibody is conjugated to APC/Cy7.
Description: A polyclonal antibody for NFkB p105 / p50 (pSer893) from Human. The antibody is produced in rabbit after immunization with human synthetic phospho-peptide from human NFkB p105 / p50 around the phosphorylation site of serine 893 (pSer893).. The Antibody is tested and validated for WB, IHC assays with the following recommended dilutions: WB (1:250-1:1000); IHC (1:25-1:100). This NFkB p105 / p50 (pSer893) antibody is conjugated to Dylight 350.
Description: A polyclonal antibody for NFkB p105 / p50 (pSer893) from Human. The antibody is produced in rabbit after immunization with human synthetic phospho-peptide from human NFkB p105 / p50 around the phosphorylation site of serine 893 (pSer893).. The Antibody is tested and validated for WB, IHC assays with the following recommended dilutions: WB (1:250-1:1000); IHC (1:25-1:100). This NFkB p105 / p50 (pSer893) antibody is conjugated to Dylight 405.
Description: A polyclonal antibody for NFkB p105 / p50 (pSer893) from Human. The antibody is produced in rabbit after immunization with human synthetic phospho-peptide from human NFkB p105 / p50 around the phosphorylation site of serine 893 (pSer893).. The Antibody is tested and validated for WB, IHC assays with the following recommended dilutions: WB (1:250-1:1000); IHC (1:25-1:100). This NFkB p105 / p50 (pSer893) antibody is conjugated to Dylight 488.
Description: A polyclonal antibody for NFkB p105 / p50 (pSer893) from Human. The antibody is produced in rabbit after immunization with human synthetic phospho-peptide from human NFkB p105 / p50 around the phosphorylation site of serine 893 (pSer893).. The Antibody is tested and validated for WB, IHC assays with the following recommended dilutions: WB (1:250-1:1000); IHC (1:25-1:100). This NFkB p105 / p50 (pSer893) antibody is conjugated to Dylight 594.
Description: A polyclonal antibody for NFkB p105 / p50 (pSer893) from Human. The antibody is produced in rabbit after immunization with human synthetic phospho-peptide from human NFkB p105 / p50 around the phosphorylation site of serine 893 (pSer893).. The Antibody is tested and validated for WB, IHC assays with the following recommended dilutions: WB (1:250-1:1000); IHC (1:25-1:100). This NFkB p105 / p50 (pSer893) antibody is conjugated to Dylight 633.
Description: A polyclonal antibody for NFkB p105 / p50 (pSer893) from Human. The antibody is produced in rabbit after immunization with human synthetic phospho-peptide from human NFkB p105 / p50 around the phosphorylation site of serine 893 (pSer893).. The Antibody is tested and validated for WB, IHC assays with the following recommended dilutions: WB (1:250-1:1000); IHC (1:25-1:100). This NFkB p105 / p50 (pSer893) antibody is conjugated to HRP.
Description: A polyclonal antibody for NFkB p105 / p50 (pSer893) from Human. The antibody is produced in rabbit after immunization with human synthetic phospho-peptide from human NFkB p105 / p50 around the phosphorylation site of serine 893 (pSer893).. The Antibody is tested and validated for WB, IHC assays with the following recommended dilutions: WB (1:250-1:1000); IHC (1:25-1:100). This NFkB p105 / p50 (pSer893) antibody is conjugated to PE/ATTO 594.
Description: A polyclonal antibody for NFkB p105 / p50 (pSer893) from Human. The antibody is produced in rabbit after immunization with human synthetic phospho-peptide from human NFkB p105 / p50 around the phosphorylation site of serine 893 (pSer893).. The Antibody is tested and validated for WB, IHC assays with the following recommended dilutions: WB (1:250-1:1000); IHC (1:25-1:100). This NFkB p105 / p50 (pSer893) antibody is conjugated to PerCP.
Description: A polyclonal antibody for NFkB p105 / p50 (pSer893) from Human. The antibody is produced in rabbit after immunization with human synthetic phospho-peptide from human NFkB p105 / p50 around the phosphorylation site of serine 893 (pSer893).. The Antibody is tested and validated for WB, IHC assays with the following recommended dilutions: WB (1:250-1:1000); IHC (1:25-1:100). This NFkB p105 / p50 (pSer893) antibody is conjugated to RPE .
Description: A polyclonal antibody for NFkB p105 / p50 (pSer893) from Human. The antibody is produced in rabbit after immunization with human synthetic phospho-peptide from human NFkB p105 / p50 around the phosphorylation site of serine 893 (pSer893).. The Antibody is tested and validated for WB, IHC assays with the following recommended dilutions: WB (1:250-1:1000); IHC (1:25-1:100). This NFkB p105 / p50 (pSer893) antibody is conjugated to Streptavidin.
Description: A polyclonal antibody for NFkB p105 / p50 (pSer907) from Human. The antibody is produced in rabbit after immunization with human synthetic phospho-peptide from human NFkB p105 / p50 around the phosphorylation site of serine 907 (pSer907).. The Antibody is tested and validated for WB, IHC, IP assays with the following recommended dilutions: WB (1:250-1:1000); IHC (1:25-1:100); IP (Various dilutions). This NFkB p105 / p50 (pSer907) antibody is conjugated to ATTO 565.
Description: A polyclonal antibody for NFkB p105 / p50 (pSer907) from Human. The antibody is produced in rabbit after immunization with human synthetic phospho-peptide from human NFkB p105 / p50 around the phosphorylation site of serine 907 (pSer907).. The Antibody is tested and validated for WB, IHC, IP assays with the following recommended dilutions: WB (1:250-1:1000); IHC (1:25-1:100); IP (Various dilutions). This NFkB p105 / p50 (pSer907) antibody is conjugated to ATTO 633.
Description: A polyclonal antibody for NFkB p105 / p50 (pSer907) from Human. The antibody is produced in rabbit after immunization with human synthetic phospho-peptide from human NFkB p105 / p50 around the phosphorylation site of serine 907 (pSer907).. The Antibody is tested and validated for WB, IHC, IP assays with the following recommended dilutions: WB (1:250-1:1000); IHC (1:25-1:100); IP (Various dilutions). This NFkB p105 / p50 (pSer907) antibody is conjugated to ATTO 655.
Description: A polyclonal antibody for NFkB p105 / p50 (pSer907) from Human. The antibody is produced in rabbit after immunization with human synthetic phospho-peptide from human NFkB p105 / p50 around the phosphorylation site of serine 907 (pSer907).. The Antibody is tested and validated for WB, IHC, IP assays with the following recommended dilutions: WB (1:250-1:1000); IHC (1:25-1:100); IP (Various dilutions). This NFkB p105 / p50 (pSer907) antibody is conjugated to ATTO 680.
Description: A polyclonal antibody for NFkB p105 / p50 (pSer907) from Human. The antibody is produced in rabbit after immunization with human synthetic phospho-peptide from human NFkB p105 / p50 around the phosphorylation site of serine 907 (pSer907).. The Antibody is tested and validated for WB, IHC, IP assays with the following recommended dilutions: WB (1:250-1:1000); IHC (1:25-1:100); IP (Various dilutions). This NFkB p105 / p50 (pSer907) antibody is conjugated to ATTO 700.
Description: A polyclonal antibody for NFkB p105 / p50 (pSer907) from Human. The antibody is produced in rabbit after immunization with human synthetic phospho-peptide from human NFkB p105 / p50 around the phosphorylation site of serine 907 (pSer907).. The Antibody is tested and validated for WB, IHC, IP assays with the following recommended dilutions: WB (1:250-1:1000); IHC (1:25-1:100); IP (Various dilutions). This NFkB p105 / p50 (pSer907) antibody is conjugated to Alkaline Phosphatase.
Description: A polyclonal antibody for NFkB p105 / p50 (pSer907) from Human. The antibody is produced in rabbit after immunization with human synthetic phospho-peptide from human NFkB p105 / p50 around the phosphorylation site of serine 907 (pSer907).. The Antibody is tested and validated for WB, IHC, IP assays with the following recommended dilutions: WB (1:250-1:1000); IHC (1:25-1:100); IP (Various dilutions). This NFkB p105 / p50 (pSer907) antibody is conjugated to APC .
Description: A polyclonal antibody for NFkB p105 / p50 (pSer907) from Human. The antibody is produced in rabbit after immunization with human synthetic phospho-peptide from human NFkB p105 / p50 around the phosphorylation site of serine 907 (pSer907).. The Antibody is tested and validated for WB, IHC, IP assays with the following recommended dilutions: WB (1:250-1:1000); IHC (1:25-1:100); IP (Various dilutions). This NFkB p105 / p50 (pSer907) antibody is conjugated to APC/Cy7.
Description: A polyclonal antibody for NFkB p105 / p50 (pSer907) from Human. The antibody is produced in rabbit after immunization with human synthetic phospho-peptide from human NFkB p105 / p50 around the phosphorylation site of serine 907 (pSer907).. The Antibody is tested and validated for WB, IHC, IP assays with the following recommended dilutions: WB (1:250-1:1000); IHC (1:25-1:100); IP (Various dilutions). This NFkB p105 / p50 (pSer907) antibody is conjugated to Dylight 350.
Description: A polyclonal antibody for NFkB p105 / p50 (pSer907) from Human. The antibody is produced in rabbit after immunization with human synthetic phospho-peptide from human NFkB p105 / p50 around the phosphorylation site of serine 907 (pSer907).. The Antibody is tested and validated for WB, IHC, IP assays with the following recommended dilutions: WB (1:250-1:1000); IHC (1:25-1:100); IP (Various dilutions). This NFkB p105 / p50 (pSer907) antibody is conjugated to Dylight 405.
Description: A polyclonal antibody for NFkB p105 / p50 (pSer907) from Human. The antibody is produced in rabbit after immunization with human synthetic phospho-peptide from human NFkB p105 / p50 around the phosphorylation site of serine 907 (pSer907).. The Antibody is tested and validated for WB, IHC, IP assays with the following recommended dilutions: WB (1:250-1:1000); IHC (1:25-1:100); IP (Various dilutions). This NFkB p105 / p50 (pSer907) antibody is conjugated to Dylight 488.
Description: A polyclonal antibody for NFkB p105 / p50 (pSer907) from Human. The antibody is produced in rabbit after immunization with human synthetic phospho-peptide from human NFkB p105 / p50 around the phosphorylation site of serine 907 (pSer907).. The Antibody is tested and validated for WB, IHC, IP assays with the following recommended dilutions: WB (1:250-1:1000); IHC (1:25-1:100); IP (Various dilutions). This NFkB p105 / p50 (pSer907) antibody is conjugated to Dylight 594.
Description: A polyclonal antibody for NFkB p105 / p50 (pSer907) from Human. The antibody is produced in rabbit after immunization with human synthetic phospho-peptide from human NFkB p105 / p50 around the phosphorylation site of serine 907 (pSer907).. The Antibody is tested and validated for WB, IHC, IP assays with the following recommended dilutions: WB (1:250-1:1000); IHC (1:25-1:100); IP (Various dilutions). This NFkB p105 / p50 (pSer907) antibody is conjugated to Dylight 633.
Description: A polyclonal antibody for NFkB p105 / p50 (pSer907) from Human. The antibody is produced in rabbit after immunization with human synthetic phospho-peptide from human NFkB p105 / p50 around the phosphorylation site of serine 907 (pSer907).. The Antibody is tested and validated for WB, IHC, IP assays with the following recommended dilutions: WB (1:250-1:1000); IHC (1:25-1:100); IP (Various dilutions). This NFkB p105 / p50 (pSer907) antibody is conjugated to HRP.
Description: A polyclonal antibody for NFkB p105 / p50 (pSer907) from Human. The antibody is produced in rabbit after immunization with human synthetic phospho-peptide from human NFkB p105 / p50 around the phosphorylation site of serine 907 (pSer907).. The Antibody is tested and validated for WB, IHC, IP assays with the following recommended dilutions: WB (1:250-1:1000); IHC (1:25-1:100); IP (Various dilutions). This NFkB p105 / p50 (pSer907) antibody is conjugated to PE/ATTO 594.
Description: A polyclonal antibody for NFkB p105 / p50 (pSer907) from Human. The antibody is produced in rabbit after immunization with human synthetic phospho-peptide from human NFkB p105 / p50 around the phosphorylation site of serine 907 (pSer907).. The Antibody is tested and validated for WB, IHC, IP assays with the following recommended dilutions: WB (1:250-1:1000); IHC (1:25-1:100); IP (Various dilutions). This NFkB p105 / p50 (pSer907) antibody is conjugated to PerCP.
Description: A polyclonal antibody for NFkB p105 / p50 (pSer907) from Human. The antibody is produced in rabbit after immunization with human synthetic phospho-peptide from human NFkB p105 / p50 around the phosphorylation site of serine 907 (pSer907).. The Antibody is tested and validated for WB, IHC, IP assays with the following recommended dilutions: WB (1:250-1:1000); IHC (1:25-1:100); IP (Various dilutions). This NFkB p105 / p50 (pSer907) antibody is conjugated to RPE .
Description: A polyclonal antibody for NFkB p105 / p50 (pSer907) from Human. The antibody is produced in rabbit after immunization with human synthetic phospho-peptide from human NFkB p105 / p50 around the phosphorylation site of serine 907 (pSer907).. The Antibody is tested and validated for WB, IHC, IP assays with the following recommended dilutions: WB (1:250-1:1000); IHC (1:25-1:100); IP (Various dilutions). This NFkB p105 / p50 (pSer907) antibody is conjugated to Streptavidin.
Spleen and thymus weight index of the model BALB / c mice increased significantly, and histopathological analysis showed a protective function of the CCP against immunosuppression caused by cyclophosphamide (CTX). In addition, the CCP has shown synergistic effects were definitely and clearly on T or B-lymphocyte proliferation induced by Cona or LPS, respectively, to promote natural killer (NK) cell activity and significantly increase the activity of phagocytes to activate peritoneal macrophages in mice immunosuppressive.
The Wobbler rat spinal cord motoneurons showed vacuolization especially, glial reaction, inflammation and abnormal glutamatergic parameters. Wobblers also showed a deficit of motor performance. This condition resembles amyotrophic lateral sclerosis (ALS). Wobbler mice also showed higher levels of corticosterone in the blood, adrenal and brain plus adrenal hypertrophy, suggesting that increased glucocorticoid prime chronic spinal cord nerve inflammation.
Therefore, we analyzed if treatment Wobbler mice with the glucocorticoid receptor (GR) antagonist reduced CORT113176 mentioned disorders. 30 mg / kg CORT113176 administered daily for 3 weeks reduced motoneuron vacuolation, decrease in astro and microgliosis, lowers inflammatory mediators group of high mobility box 1 protein (HMGB1), pulses like receptor 4, myeloid differentiation primary response 88 (MyD88), p50 subunit factor nuclear kappa B (NF), tumor necrosis factor (TNF) receptor, and interleukin 18 (IL18) compared with untreated Wobblers. CORT113176 improve survival signal pAkt (serine-threonine kinases) and a decrease in phosphorylated death signal Trash-N-terminal kinase (pJNK), symptoms of anti-apoptotic.
There was a moderate positive effect on glutamine synthase and astrocyte glutamate transporters, showed a decrease in glutamate excitotoxicity. In these pre-clinical studies, Wobblers receive CORT113176 show increased resistance to fatigue in the rota rod test and atrophy of the lower front leg in Week 2- 3. Therefore, the long-term treatment with attenuated CORT113176 degeneration and inflammation, improve motor performance and decrease foot deformities. Antagonism of GR may be a potential therapeutic value for neurodegenerative diseases.
Long-term effects of the glucocorticoid receptor modulator cort 113176 in murine motoneuron degeneration.
resistin expression in human monocytes is controlled by two SNPs associated promoter binding mediation NFkB p50 / p50 and C-methylation.
Resistin is a key cytokine associated with metabolic and inflammatory diseases. Especially in East Asian populations, the level of expression is strongly influenced by genetic polymorphisms. The mechanism and functional implications of this genetic control remains unknown. By using the test reporter, EMSA, the study of inhibition, sequencing of bisulfite, CHIP-Seq and gene-editing we showed that the homodimer p50 / p50 is known to act as a repressor for a number of genes of pro-inflammation plays a central role in the genetic regulation of resistin in monocytes along with promoter methylation.
RETN common haplotype in the p50 / p50 offset constitutive expression by binding to the promoter. In a variant haplotypes Asia but this interaction is disrupted by the A allele of rs3219175. SNP is a very close relationship with rs34861192, a SNP CpG, located 280 bp upstream of the supply site C-allele-specific methylation.
rs34861192 lies in the region of 100 bp was found methylated haplotype similarities but not in Asia, so that the latter have a higher basal expression, which also associates with increased histone acetylation (H3K27ac). genotype associations in cohort data from 200 East Asians revealed a significant association between this haplotype and plasma levels of factors such as TGF-b, S100B, sRAGE and IL-8 as well as the number of myeloid DC.
Thus, a common haplotype RETN tightly regulated by epigenetic mechanisms associated with p50 / p50-binding. This control is missing in the Asian haplotypes, which may have evolved to balance antagonistic effects on the protection RETN pathogen induction vs metabolism and inflammatory diseases.
Transcription factor NF has been associated with the timing of menopause in human genome-wide association studies were great. Additionally, preclinical studies indicate that the loss of tumor necrosis factor alpha (TNF) or receptor activation Tnfr2 slow the growth of primordial follicles (PFGA). Although TNFa: receptor signaling stimulates the NF and may mechanically connect these findings, very little is known about the signal NF PFGA.
Because the downstream signal TNFa / Tnfr2 ligand / receptor interactions has not been questioned as pertaining to PFGA, we evaluated the expression of key proteins in the signal NF and growing primordial follicles, as well as during the aging ovaries. We show that the key members of the pathway NF, including subunit, activating kinase and inhibitory proteins, expressed in murine ovary. In addition, the p65 and p50 subunits, and cytosolic inhibitory protein IκBα and IκBβ, which is present in the ovarian follicle, including the primordial stage. Finally, we assess PFGA in mice genetically modified (AKBI) previously shown to be resistant to stress-induced inflammatory activation of NF because of excessive inhibition of protein NF IκBβ.
Consistent with the hypothesis that NF play a key role in PFGA, rats showed slower AKBI PGFA from the wild type (WT) control, and their ovaries contain nearly twice the number of primordial follicles as WT good at the beginning and end of reproductive age. These data provide mechanistic insights on the control of PFGA and suggest that targeting NF on IκB protein level may be obedient to slow the pace of these PFGA in women faced with the early death of the ovaries.
Control of Murine Primordial Follicle Growth Activation by IκB/NFκB Signaling
Effects of Granulocyte Macrophage Colony-Stimulating Factor Inhibition of skin / nerve Cells In Vitro Model
The study was based on the concept of neuro-aging and how it can affect the surrounding skin cells. It has been proven that a lot of factors that play an important role in the homeostasis of the skin by interfering with various cytokines, either through activation or inhibition. Granulocyte macrophage colony-stimulating factor (GM-CSF) is generally recognized as an inflammatory cytokine, and our previous research has shown its effects on neuronal aging after ultraviolet (UV) irradiation of skin cells.
Following our previous work, this study was conducted to investigate the neuroprotective effects of GM-CSF antagonist, and how it may play an important role in mediating the anti-aging and anti-inflammatory effects in keratinocytes models / neural aging. When the cells were blastoma man (SH-SY5Y) were treated with 10 ng / ml GM-CSF, RNA level rules associated with aging, such as matrix metalloproteinase-9 (MMP9), nuclear factor NF-kappa-B p50 subunit (NFkB) , inducible nitric oxide synthase (iNOS) and interleukin 1 beta (IL-1β) increased, whereas GM-CSF inhibition causes decreased their expression.
The decline in the antioxidant, glutathione (GSH) was observed after the SH-SY5Y cells treated with GM-CSF. This study confirms that the GM-CSF antagonist may play an important role in the aging of nerves, in which inhibition may be a new target in the skin / nerve aging model.Erinacine A, which is one of the major diterpenoid bioactive compounds extracted from cultured mycelia of H. erinaceus, featuring great antitumorigenic activity.
TRAF Family Member Associated NFKB Activator (TANK) Antibody
Description: A Rabbit polyclonal antibody against Human, Pig TRAF Family Member Associated NFKB Activator (TANK). This antibody is labeled with APC-Cy7.
TRAF Family Member Associated NFKB Activator (TANK) Polyclonal Antibody (Human, Pig), Biotinylated
Description: A Rabbit polyclonal antibody against Human, Pig TRAF Family Member Associated NFKB Activator (TANK). This antibody is labeled with Biotin.
Recombinant Human TRAF Family Member-Associated NFKB Activator
Description: TANK Human Recombinant produced in E.Coli is a single, non-glycosylated polypeptide chain containing 448 amino acids (1-425a.a) and having a molecular mass of 50.2kDa. TANK is fused to a 23 amino acid His-tag at N-terminus & purified by proprietary chromatographic techniques.
Tank (untagged ORF) – Rat TRAF family member-associated NFKB activator (Tank), (10 ug)
However, the molecular mechanisms underlying erinacine A induces cancer cell apoptosis in colorectal cancer (CRC) remains unclear. The study found that treatment with erinacine A not only triggers the activation of the extrinsic apoptotic pathway (TNFR, Fas, FasL, and caspases) but also suppress the expression of antiapoptotic molecule Bcl-2 and Bcl-XL through a time-dependent manner in DLD -1 cells.
The application of peptides rationally designed therapy (TP) can improve the outcome of cancer treatment. This peptide hold the potential to directly target and stimulate proliferation pathways arrest or cell death pathways. Elastin like polypeptide (ELP) is a biopolymer derived elastin which undergoes a phase transition thermal mediated.
This study using p50, a nuclear localization sequence derived peptide that inhibits the activation of NF and is involved in cancer cell survival and metastasis. In order to effectively delivery of p50, the conjugation SynB1-ELP1, thermally responsive macromolecular carrier. By applying an external heat source, lightly Hyperthermic conditions (41 ° C) to induce aggregation and therefore can be used to specifically target the ELP for solid tumors in cancer therapy.
The addition of cell penetrating peptides (the CPP) with the N-terminus of the carrier macromolecule improving cellular uptake and direct the subcellular localization of bioactive peptides. Novel TP, p50, inhibit proliferation and induce apoptosis of breast cancer cells by blocking imports of intranuclear NF. By expanding the repertoire of oncogenic targets, CPP, and the size of the ELP carrier, based on ELP polypeptide may be modulated to optimize the delivery of new therapies and allow for flexibility to create individualized cancer therapy.
Thermally Targeted p50 Peptide Inhibits Proliferation and Induces Apoptosis of Breast Cancer Cell Lines
Upregulation of miR-133a-3p in the sciatic nerve Contribute to Development of Neuropathic Pain
Micro (mi) RNAs expressed in the sciatic nerve of streptozotocin (STZ) -induced diabetic rats were evaluated in terms of potential therapies in patients with diabetic neuropathic pain (DNP). Relative miRNA expression in the sciatic nerve with DNP analyzed using next-generation sequencing and quantitative PCR. potential downstream target miRNAs allegedly using Ingenuity Pathway Analysis and TargetScan database.
In vitro experiments were performed using Schwann cells RSC96 miR-133a-3p-transfected. We do blotting and immunofluorescence analysis of micro-West and West to verify the role of miR-133a-3p. In vivo, the relationship between miR-133a-3p with DNP analyzed through AAV-miR-133a-3p intraneural (intra-epineural but extrafascicular) injection into the sciatic nerve of normal mice or injection of miR-133a-3p antagomir to the sciatic nerve of diabetes mellitus ( DM) rats.
miR-133a-3p mimics transfected into Schwann cells RSC96 increased VEGFR-2, p38α MAPK, TRAF-6, and the expression of p50 NF PIAS3 and reduce MKP3 and expression. In normal rats, AAV-miR-133a-3p delivery through intraneural injection into sciatic nerve induced mechanical allodynia and p-p38 MAPK activation. At DM rats, administration of miR-133a-3p antagomir alleviated DNP and downregulated p-p38 phosphorylation. Overexpression of miR-133a-3p on the pain induced by sciatic nerve. We suggest that miR-133a-3p is a potential therapeutic target for DNP.
Immunoregulatory effects and mechanisms of immunological response of Craterellus cornucopioides (L.) Pers. polysaccharides (CCP) with a triple-helix structure in peritoneal macrophages was investigated in vitro for the first time. This study showed that treatment of peritoneal macrophages with 80 ug / mL PKC for 48 hours significantly strengthen their phagocytic function and increased activity of lysozyme (LZM), acid phosphatase (ACP) and succinodehydrogenase (SDH) when compared to the untreated group.
Description: A sandwich quantitative ELISA assay kit for detection of Human NFKB Repressing Factor (NKRF) in samples from tissue homogenates or other biological fluids.
Description: A sandwich quantitative ELISA assay kit for detection of Human NFKB Repressing Factor (NKRF) in samples from tissue homogenates or other biological fluids.
Furthermore, Western blot and quantitative real-time polymerase chain reaction (qRT-PCR) assay showed that 80 ug / mL PKC activated macrophages, significantly increased the mRNA expression of cytokines (IL-8, IL-1β, IFN-α and TNF-α ) and upregulated the expression of TLR4 cell membrane receptor protein, and protein kinase downstream product (MyD88, TAK1, P-IKKα / β, and P-MEK) via activation of TLR4-NF in peritoneal macrophages.
 Antibody)
 Antibody)
)
)
)
)
)
)
)
 Antibody)
)
 NFKB2 Antibody)
 NFKB1 Antibody)
)
)
 Antibody)
)
)
)
)
)
)
)
)
)
 Antibody)
 Antibody)
 Antibody)
 Antibody)
)
)
)
 Rabbit Monoclonal Antibody)
 polyclonal antibody)
 Antibody)
 Antibody)
 Antibody)
 Antibody)
 Antibody)
 Antibody)
 Antibody)
 Antibody)
 Antibody)
 Antibody)
 Antibody)
 Antibody)
 Antibody)
 Antibody)
 Antibody)
 Antibody)
 Antibody)
 Antibody (Phospho-specific))
 Antibody (Phospho-specific))
 Antibody (Phospho-specific))
 Antibody (Phospho-specific))
 Antibody (Phospho-specific))
 Blocking Peptide)
 Blocking Peptide)
 Blocking Peptide)
 Blocking Peptide)
 Blocking Peptide)
 Blocking Peptide)
 Blocking Peptide)
 Antibody)
)
 Polyclonal Antibody)
 Protein)
)
 ELISA Kit)
 Polyclonal Antibody (Human, Pig))
 Polyclonal Antibody (Human, Pig), PE)
)
 Polyclonal Antibody (Human, Pig), APC)
 Polyclonal Antibody (Human, Pig), Cy3)
 Polyclonal Antibody (Human, Pig), FITC)
 Polyclonal Antibody (Human, Pig), HRP)
)
)
)
)
)
 Antibody Pair Kit (with Standard))
)
 Polyclonal Antibody (Human, Pig), APC-Cy7)
 Polyclonal Antibody (Human, Pig), Biotinylated)
)
 - Rat TRAF family member-associated NFKB activator (Tank), (10 ug))
 - Rat TRAF family member-associated NFKB activator (Tank), transcript variant 2)
-Human TRAF family member-associated NFKB activator (TANK), transcript variant 2)
-Human TRAF family member-associated NFKB activator (TANK), transcript variant 1)
 - Rat TRAF family member-associated NFKB activator (Tank), (10 ug))
 - Human TRAF family member-associated NFKB activator (TANK), transcript variant 2)
 - Human TRAF family member-associated NFKB activator (TANK), transcript variant 1)
 - Homo sapiens TRAF family member-associated NFKB activator (TANK), transcript variant 3)
 - Rat TRAF family member-associated NFKB activator (Tank), 200ul, >10^7 TU/mL” width=”100″ height=”100″> <span style=)
 - Rat TRAF family member-associated NFKB activator (Tank), transcript variant 2)
-Human TRAF family member-associated NFKB activator (TANK), transcript variant 2)
-Human TRAF family member-associated NFKB activator (TANK), transcript variant 1)
 - Homo sapiens TRAF family member-associated NFKB activator (TANK), transcript variant 3)
 - Rat TRAF family member-associated NFKB activator (Tank), 200ul, >10^7 TU/mL” width=”100″ height=”100″> <span style=)
 - Homo sapiens TRAF family member-associated NFKB activator (TANK), transcript variant 3)
 - Rat TRAF family member-associated NFKB activator (Tank), (10 ug))
, transcript variant 1, mGFP tagged)
 Antibody)
 - Rat TRAF family member-associated NFKB activator (Tank), (10 ug))
-Human TRAF family member-associated NFKB activator (TANK), transcript variant 2, 200ul, >10^7 TU/mL” width=”100″ height=”100″> <span style=)
 - Human TRAF family member-associated NFKB activator (TANK), transcript variant 1, 200ul, >10^7 TU/mL” width=”100″ height=”100″> <span style=)
)
 - Human TRAF family member-associated NFKB activator (TANK), transcript variant 1, 200ul, >10^7 TU/mL” width=”100″ height=”100″> <span style=)
 transcript variant 2 for miRNA target validation)
 transcript variant 1 for miRNA target validation)
-Human TRAF family member-associated NFKB activator (TANK), transcript variant 2)
, transcript variant 1, Myc-DDK-tagged)
 Protein)
 Antibody (HRP))
 Antibody)
)
 Antibody Pair)
)
 Polyclonal Antibody)
 Protein)
 (AP))
 (PE))
 (APC))
 (HRP))
)
 CLIA Kit)
 (FITC))
)
 ELISA Kit)
